Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Melanoma and Skin Cancer

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Lancet Oncol

Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM

doi: 10.1016/S1470-2045(24)00338-3

Melanoma and Skin Cancer

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study

Melanoma Res

González-Barrallo I, Castellón Rubio VE, Medina J, España Fernández S, Mujika K, Majem M, Aguado C, Cabrera Suárez MÁ, Palacio I, Osterloh L, Martínez-Fernández A, García-Castaño A

doi: 10.1097/CMR.0000000000001020

Melanoma and Skin Cancer

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

J Clin Oncol

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D

doi: 10.1200/JCO.24.01125

Melanoma and Skin Cancer

Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States

Melanoma Res

Chandrasekaran S, Ling YL, Tang J

doi: 10.1097/CMR.0000000000000990

Melanoma and Skin Cancer

Effect of patient-contextual skin images in human- and artificial intelligence-based diagnosis of melanoma: Results from the 2020 SIIM-ISIC melanoma classification challenge

J Eur Acad Dermatol Venereol

Kurtansky NR, Primiero CA, Betz-Stablein B, Combalia M, Guitera P, Halpern A, Kentley J, Kittler H, Liopyris K, Malvehy J, Rinner C, Tschandl P, Weber J, Rotemberg V, Soyer HP

doi: 10.1111/jdv.20479

Melanoma and Skin Cancer

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

J Eur Acad Dermatol Venereol

Schumann K, Klespe KC, Mauch C, Loquai C, Schultheis U, Börger S, Thiem A, Emmert S, Hoellwerth M, Koelbinger P, Nguyen VA, Wanner M, Richtig E, Peitsch WK, Harth W, Zenderowski V, Braun AD, Mengoni M, Dummer R, Mangana J, Maul LV, Meis F, Rappersberger K, Persa OD, Biedermann T, Posch C

doi: 10.1111/jdv.20708

Melanoma and Skin Cancer

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Melanoma Res

Al-Naesan I, Krepper D, Sparano F, Sztankay M, Efficace F, Giesinger JM

doi: 10.1097/CMR.0000000000001014

Melanoma and Skin Cancer

High dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind, placebo-controlled study (ViDMe trial)

Br J Dermatol

De Smedt J, Van Kelst S, Janssen L, Marasigan V, Boecxstaens V, Bogaerts K, Belmans A, Vanderschueren D, Vandenberghe K, Bechter O, Aura C, Lambrechts D, Strobbe T, Emri G, Nikkels A, Garmyn M

doi: 10.1093/bjd/ljae257

Allergic Diseases

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial

Allergy

Zielen S, Bernstein JA, Sturm GJ, Jutel M, Pfaar O, RESONATE Investigator Group, Shamji MH, Mösges R, Berger M, Berger UE, DuBuske L, Layhadi JA, Klimek L, Ollert M, Skinner MA, Kramer MF, de Kam PJ

doi: 10.1111/all.16491

Related content

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States

Effect of patient-contextual skin images in human- and artificial intelligence-based diagnosis of melanoma: Results from the 2020 SIIM-ISIC melanoma classification challenge

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

High dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind, placebo-controlled study (ViDMe trial)

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial